Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study

What Was Tested

Researchers studied Macimorelin (non-peptide) in this randomized controlled trial publication.

Macimorelin is an orally active ghrelin receptor agonist indicated for the diagnosis of adult growth hormone (GH) deficiency in the United States.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Safety was assessed based on treatment-emergent adverse events (TEAEs), vital signs, 12‑lead electrocardiograms, and laboratory parameters.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Macimorelin (non-peptide) and who got the comparison, which limits bias.

As a double-blind Macimorelin (non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Macimorelin (non-peptide), giving a reference point.

What Was Measured

The subject headings attached to it are Healthy Volunteers, Human Growth Hormone, Indoles, Tissue Distribution and Tryptophan.

The authors tagged it with the keywords Growth hormone deficiency, Macimorelin and Safety.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Macimorelin (non-peptide).

Results are reported in around 14 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Macimorelin (non-peptide) compound page, all human trials.